TCT-264 Relation between peak high sensitivity CRP levels before coronary angiography and culprit lesion morphology in non-ST-segment elevation acute coronary syndrome -An optical coherence tomography study–  by Saka, Kenichiro et al.
TCT-261
Five-Year Clinical Outcomes of the OLIVUS-Ex (Impact of OLmesartan on
progression of coronary atherosclerosis: Evaluation by IntraVascular
UltraSound Extension) Trial
Atsushi Hirohata1, Eiki Hirose1, Yuhei Kobayashi1, Minako Ohara1, Tohru Ohe1,
Fumihiko Sano1, Hiroya Takafuji1, Hiroyuki Takinami1, Keizo Yamamoto1,
Ryo Yoshioka1
1The Sakakibara Heart Institute of Okayama, Okayama, Japan
Background: The OLIVUS trial, using volumetric IVUS, reported a positive role in
achieving a potentially lower rate of coronary atheroma progression through the
administration of Olmesartan, an angiotension-II receptor blocker (ARB), for stable
angina pectoris (SAP) patients requiring percutaneous coronary intervention (PCI).
However, the benefits between ARB administration on long-term clinical outcomes and
serial atheroma changes by IVUS remain unclear. Thus, we examined the 5-year clinical
outcomes from OLIVUS according to treatment strategy with Olmesartan.
Methods: In the OLIVUS trial, serial volumetric IVUS examinations (baseline and 14
months) were performed in 247 patients with SAP. When patients underwent PCI for
culprit lesions, IVUS was performed in their non-culprit vessels. Patients were randomly
assigned to receive 20-40mg of Olmesartan or control, and treated with a combination of
-blockers, calcium channel blockers, diuretics, glycemic control agents and/or statins per
physician’s guidance. Five-year clinical outcomes and annual progression rate of
atherosclerosis, assessed by IVUS (mean lengths 43mm), were compared with major
adverse cardio- and cerebrovascular events (MACCE).
Results: Cumulative event-free survival was significantly higher in the Olmesartan group
than in the control group (p0.04; log-rank test). By adjusting for validated prognosti-
cators, Olmesartan administration was identified as a good predictor of MACCE (HR
0.73, 95%CI 0.49-0.88; p0.04). On the other hand, patients with adverse events (n38)
had larger annual atheroma progression than the rest of the population (22.417.9% vs.
2.414.1%, P0.001).
Control Olmesartan p-value
n 121 126
14-months follow-up (%)
Plaque Volume Change 5.4 15.5 0.6 12.9 0.016
Percent Change in Plaque Volume 3.6 9.5 0.7 8.4 0.038
In-stent Restenosis 10.7 7.9 0.42
5-Years Follow-up (%)
Composite MACCE 20.4 10.4 0.034
Cardio-, cerebral Death 2.2 1.2 0.75
Non-fatal Stroke 1.7 0.3 0.08
Myocardial Infarction 1.6 1.6 0.89
Unstable/Progressive Angina 12.4 6.5 0.10
(Culprit Related/De novo Lesions) (5.4/6.8) (3.4/3.1)
Deteriation of Heart/Renal Failure 2.5 0.8 0.30
Conclusions: Olmesartan therapy appears to confer improved long-term clinical out-
comes. Atheroma volume changes, assessed by IVUS, seem to be a reliable surrogate for
future MACCE in this study cohort.
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Background: Prior studies have shown that statin may stabilize atheromatous plaques by
increasing fibrous-cap thickness. The aim of this study was to examine statin pretreatment
on plaque vulnerability assessed by intravascular ultrasound (IVUS) and optical coher-
ence tomography (OCT) in patients with stable angina pectoris (SAP).
Methods: Culprit plaques in 110 patients with SAP were interrogated by both IVUS and
OCT before percutaneous coronary intervention (PCI). Volumetric analyses were per-
formed for external elastic membrane (EEM), lumen, and plaque plus media at 1-mm
intervals for 11 IVUS images per patient. The thinnest part of the fibrous cap was
measured by OCT.
Results: In patients with statin pretreatment, low density lipoprotein-cholesterol (LDL-C)
level (n  73) was lower than those without statin pretreatment (n  37) (80mg/dl vs.
113mg/dl, P0.01). Patients with statin pretreatment had smaller EEM volume, plaque plus
media volume, and plaque burden than those without (107 mm3 vs. 129 mm3, P0.05, 65
mm3 vs. 91 mm3, P0.01, and 62% vs. 71%, p 0.01, respectively). By OCT, Patients with
statin pretreatment had a lower incidence of lipid rich plaque than those without (43% vs. 68%,
P0.02). Statin pretreatment was associated with thicker fibrous cap thickness (115m vs
90m, P0.03) and fewer incidence of thin-cap fibroatheroma (TCFA) (6% vs. 22%, p 
0.02). Multivariate logistic regression analysis identified statin pretreatment as a negative
determinant of lipid rich plaque and TCFA independent of age, gender, LDL-C, and
high-sensitivity C-reactive protein (odds ratio 0.36; 95% CI 0.16–0.83, p  0.02 and odds
ratio 0.21; 95% CI 0.06–0.75, p  0.02, respectively).
Conclusions: In patients with SAP, lack of statin pretreatment was associated with larger
plaque volume and more vulnerable plaque morphology independent of LDL-C levels.
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Background: Angiographic ectasias and aneurysms in stented segments have been
associated with a risk of late stent thrombosis. Using optical coherence tomography
(OCT) at follow-up, some stented segments show coronary evaginations reminiscent of
ectasias. The occurrence, predictors and mechanisms of evaginations following drug-
eluting stent (DES) implantation are unknown.
Methods: Evaginations were defined as outward bulges in the luminal contour between
struts. They were considered major evaginations (ME) when present in 3 consecutive
frames, with a depth 10% of the stent diameter. A total of 228 patients who had
sirolimus (SES)-, paclitaxel-, biolimus-, everolimus (EES)-, or zotarolimus (ZES)-eluting
stents implanted in 254 lesions, were analysed after 1, 2 or 5 years; and serial assessment
using OCT and intravascular ultrasound (IVUS) was performed post intervention and
after 1 year in 42 patients.
Results: ME occurred frequently at all time points in SES (26%) and were rarely seen
in EES (3%) and ZES (2%, p0.003). SES implantation was the strongest independent
predictor of ME (adjusted OR [95% CI]: 10.3 [1.3-85.5, p0.01). Malapposed and
uncovered struts were more common in lesions with vs. without ME (77% vs. 25%,
p0.001, and 95% vs. 20%, p0.001, respectively). Post-intervention intra-stent dissec-
tion and protrusion of the vessel wall into the lumen were associated with an increased risk
of evagination at follow-up (OR [95% CI]: 2.9 [1.8-4.9], p0.001 and 3.3 [1.6-6.9],
p0.001, respectively). In paired IVUS analyses, ME showed a larger increase in the
external elastic membrane area (20% area change) compared with lesions without ME
(5% area change, p0.001).
Conclusions: OCT-detected coronary evaginations are a morphological footprint of
early-generation SES and are nearly absent in newer-generation DES. Evaginations
appear to be related to vessel injury at baseline, and are mainly caused by positive vessel
remodeling.
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Background: C-reactive protein (CRP) levels sometimes elevate during admission
without any inflammatory symptom after onset of acute coronary syndrome, although its
clinical significance remains unknown. In this study, we investigated the relation between
peak high sensitivity CRP (hs-CRP) levels and culprit lesion morphology by optical
coherence tomography study (OCT) in the acute phase of non-ST-segment elevation acute
coronary syndrome (NSTEACS).
Methods: Culprit plaques in 100 patients with NSTEACS, who received elective
percutaneous coronary intervention (PCI), were interrogated by OCT before PCI. The
blood samples were obtained from all patients 0, 3, and 6 hours after admission and every
day until coronary angiography. Patients were divided into high peak hs-CRP group (peak
hs-CRP 50 mg/l) and low peak hs-CRP group (peak hs-CRP50 mg/l) on the basis of
highest hs-CRP levels before coronary angiography.
Results: Patients in high peak hs-CRP group (N23) had higher Troponin I levels than
those in the low peak hs-CRP group (N77) (0.17ng/ml vs. 0.07ng/ml, P0.02). We
observed significantly more plaque rupture (78% vs. 47%, P0.01), thrombus (96% vs.
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69%, P0.01), and microchannel (61% vs. 32%, P0.02) in the high peak hs-CRP group
than the low peak hs-CRP group. A multivariate logistic regression model revealed that
high peak hs-CRP levels correlated with the presence of ruptured plaque and microchan-
nel (odds ratio 5.19, P  0.01 and odds ratio 4.18, P  0.01, respectively).
Conclusions: High peak hs-CRP was associated with the presence of ruptured plaque
and neovascularization, suggesting that elevation of hs-CRP during admission may reflect
greater plaque vulnerability in the setting of NSTEACS.
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Background: Both large plaque burden and low wall shear stress (WSS) have been
associated with coronary plaque progression. We hypothesized that segments with a
combination of large plaque burden and low WSS show greater plaque progression than
segments with either large plaque burden or low WSS alone.
Methods: Twenty patients with non-obstructive coronary artery disease (CAD), treated
with 80 mg/day atorvastatin, underwent baseline and 6-month follow-up intravascular
ultrasound (IVUS) and Doppler velocity assessments, and computational fluid dynamics
modeling in left anterior descending coronary artery for calculation of WSS. Change in
plaque area (follow-up plaque area – baseline plaque area) was calculated in 0.5mm IVUS
segments with low WSS (defined as 10 dynes/cm2) and large plaque burden (40%).
Results: Mean age was 5412, 65% were men, and 35% had diabetes. Of the 2,249
VH-IVUS frames analyzed (median: 120, interquartile range: 80 to 133 frames per artery),
43% had plaque burden 40%, 9% had low WSS, and only 1% had both plaque burden
40% and low WSS at baseline. The combination of plaque burden40% and low WSS
was associated with significantly greater change in plaque area at follow-up (	0.681.05
mm2), compared to presence of plaque burden 40% alone (-0.281.32 mm2) or low
WSS alone (	0.050.71 mm2) (p0.05) (Figure).
Conclusions: In patients with CAD treated with high dose statins, coronary segments
with the combination of plaque burden 40% and low WSS have greater plaque
progression than segments with low WSS alone.
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Background: Calcification in a ’spotty’ distribution is hypothesized to be an ultrasonic
marker of vulnerable plaque, yet the relationship between spotty calcification and
underlying plaque composition has not been fully delineated. Using combined intracoro-
nary near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS), we describe
the frequency of spotty calcification among lipid-core plaques (LCP).
Methods: In 21 consecutive patients undergoing NIRS-IVUS prior to percutaneous
intervention, NIRS was used to identify LCP (bright yellow signal on the NIRS block
chemogram). The lipid content was quantified by the lipid-core burden index (LCBI).
Throughout the length of each LCP, IVUS images were analyzed every 1 mm for
calcification. Spotty calcification was defined as an arc of calcification 90°.
Results: A LCP (evident by bright yellow in the central block chemogram) by
NIRS-IVUS is shown (Figure). Spotty calcification is present (arrows). Among 23
consecutive LCP identified by NIRS (length 7.14.7 mm; LCBI 319143), spotty
calcification was present in 87.0%. Calcification was distributed throughout the length of
LCP, found in 161 of 190 (84.7%) IVUS frames analyzed. Within LCPs, spotty
calcification was significantly more common than the absence of calcification (40.0%
frames vs 15.3% frames, p0.0001).
Conclusions: Spotty calcification is commonly associated with LCP and is distributed
throughout its length. The observed association between spotty calcification and LCP is
consistent with the concept that spotty calcification may be a marker of vulnerable lesions.
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Background: Plaque components of non-culprit lesion (NCL) in acute coronary
syndrome (ACS) patients (ACS-NCL) have not been compared to those of target lesion
(TL) in stable angina (SA) patients (SA-TL). We used virtual histology-intravascular
ultrasound (VH-IVUS) to compare the plaque components between ACS-NCL and
SA-TL.
Methods: We compared VH-IVUS findings between non-culprit lesion in 290 ACS
patients (ACS-NCL) and target lesion in 276 SA patients (SA-TL). VH-IVUS classified
the color-coded tissue into four major components: green (fibrotic, FT); yellow-green
(fibro-fatty, FF); white (dense calcium, DC); and red (necrotic core, NC). Thin-cap
fibroatheroma (TCFA) was defined as a NC  10% of plaque area in at least 3
consecutive frames without overlying fibrous tissue in the presence of  40% plaque
burden.
Results: Although plaque burden was significantly smaller (5213% vs. 5414%,
p0.044), ACS-NCL had greater %NC area (17.911.6% vs. 14.38.7%, p0.001) and
%DC area (9.79.8% vs. 8.18.0%, p0.032) compared with SA-TL at the minimum
lumen site. By volumetric analysis, ACS-NCL had greater %NC volume (15.89.2% vs.
13.97.4%, p0.006) compared with SA-TL. TCFA was observed more frequently in
ACS-NCL compared with SA-TL (14.1% vs. 9.8%, p0.042). Independent predictors of
TCFA by multivariate analysis were ACS [odds ratio (OR): 2.204, 95% CI: 1.321-3.434,
p0.021), high-sensitivity C-reactive protein (OR: 1.101; 95% CI 1.058-1.204,
p0.035), and low-density lipoprotein cholesterol (OR: 1.013; 95% CI 1.006-1.020,
p0.041).
Conclusions: ACL-NCL had more vulnerable plaque component compared with SA-TL
and ACS, high-sensitivity C-reactive protein, and low-density lipoprotein cholesterol
were the independent predictors of TCFA in this study.
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